cabozantinib
exelixis
['crpc', 'cabozantinib']
 agree. at the same ballpark here would be the cabozantinib in mcrpc with improvement in several endpoints but not os, and it did not move forward. #asco22
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer